MarginsXMarginsX
Home › Markets › Health Care › PCSA

Processa Pharmaceuticals Inc. (PCSA)

PCSA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.72
-7.53% on the day
Market cap
$4.8M
Nano cap
Revenue · 2022
$0
Prior year not contiguous
Net income · 2022
-$27.4M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1533743/000149315223009730/0001493152-23-009730-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.

Profile

FieldValue
TickerPCSA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001533743
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2022

LineValue
Revenue$0
Net income-$27.4M
Operating income-$27.5M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$6.5M
Total assets$8.6M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
0.2 months
$196K cash at June 30, 2026
Share count, 1 year
+23.5%
2025-11-03 to 2026-11-09 · +5580.2% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$209K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Accordingly, we concluded that substantial doubt about our ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued."
10-Q 2026-11-13
Cash and burn$196K cash; operating cash flow -$3.0M a quarter.Report 2026-06-30
Shares outstanding2,798,241 (2026-11-09); 56,644,223 a year earlier; 24,631,474 three years earlier. 1y figure adjusted for splits (1-for-25 overall); 3y figure adjusted for splits (1-for-500 overall).Cover page 2026-11-09
Reverse splits, 3 years2; latest 1-for-25 on 2025-12-17Source 2025-12-17
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-10-09
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCherry Bekaert LLP, Tampa, Florida, United StatesPCAOB Form AP 2026-03-19
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $209K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$3.3M-$2.0M$196KNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$3.4M-$3.6M$1.7MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$3.4M-$2.9M$5.5MNo debt tagsNeeds four quarters10-K 2026-03-18
Q3 2025
2025-09-30
Not filed-$3.4M-$3.5M$6.3MNo debt tagsNeeds four quarters10-Q 2025-11-06
Q2 2025
2025-06-30
Not filed-$3.9M-$2.3M$6.9MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$2.8M-$2.7M$2.9MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$2.7M-$2.2M$1.2MNo debt tagsNeeds four quarters10-K 2026-03-18
Q3 2024
2024-09-30
Not filed-$3.4M-$3.6M$2.9MNo debt tagsNeeds four quarters10-Q 2025-11-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-10-09
Latest annual report10-K/A2026-04-30
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-11-05

Source: SEC EDGAR submissions feed, 706 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.6%
1 month+5.1%
3 months-25.6%
Year to date-35.4%
1 year-74.5%
From 52-week high-75.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PULMPulmatrix Inc.$1.33+2.31%$4.9M
CANFCan-Fite Biopharma Ltd$1.56+9.86%$4.7M
SCNXScienture Holdings Inc.$2.99+3.10%$4.9M
SKYESkye Bioscience Inc.$1.06-2.29%$4.7M
CVKDCadrenal Therapeutics Inc.$1.40-7.28%$5.0M
CNSPCNS Pharmaceuticals Inc.$3.48+20.42%$5.1M
JAGXJaguar Health Inc.$0.3864-7.74%$5.2M
NCNANuCana plc American Depositary Share$0.8631-7.46%$4.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier